Abstract
Objective Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that increases the risk of cardiovascular disease, but the causal relationship has remained unknown in the East Asian population. We aim to determine the causal relationship between SLE and congestive heart failure (CHF) in the East Asian population.
Methods We conducted a two-sample Mendelian randomization (MR) study to examine the potential causal association of SLE with CHF, using the East Asian genome-wide association study datasets for SLE (4,222 cases, 8,431 controls) and CHF (9,413 cases, 203,040 controls).
Results The MR analysis showed that genetic susceptibility to SLE was associated with the increased risk of CHF (odds ratio [OR] 1.032, 95% confidence interval [CI] 1.004–1.061, P=0.023). After excluding the human leukocyte antigen (HLA) regions, SLE was also associated with a higher risk of CHF (OR 1.034, 95% CI 1.007–1.062, P=0.015). The multiple MR sensitivity analyses confirmed that this potential causal association was unlikely to be biased by horizontal pleiotropy.
Conclusions The findings of this MR study suggest that SLE potentially increases the risk of CHF in the East Asian population. Genetic predisposition to SLE may play a significant role in developing CHF in the East Asian population.
What is already known on this topic
- Patients with systemic lupus erythematosus (SLE) have a higher risk of congestive heart failure (CHF) in the European and East Asian populations.
What this study adds
- The Mendelian randomization analysis suggests that genetic susceptibility to SLE was associated with a higher risk of CHF in the East Asian population.
- Non-human leukocyte antigen (HLA) variants associated with SLE were also associated with the increased risk of CHF.
How this study might affect research, practice, or policy
- Genetic predisposition to SLE may be useful to understand CHF risk stratification and management in the East Asian population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used only publicly available GWAS summary statistics datasets at https://gwas.mrcieu.ac.uk/.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest: None.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.